Royalty Pharma PLC (RPRX): Price and Financial Metrics

Royalty Pharma PLC (RPRX): $39.19

0.55 (+1.42%)

POWR Rating

Component Grades













Add RPRX to Watchlist
Sign Up

Industry: Biotech



in industry


  • RPRX scores best on the Stability dimension, with a Stability rank ahead of 94.57% of US stocks.
  • The strongest trend for RPRX is in Quality, which has been heading down over the past 177 days.
  • RPRX's current lowest rank is in the Momentum metric (where it is better than 22.96% of US stocks).

RPRX Stock Summary

  • RPRX has a market capitalization of $23,505,555,684 -- more than approximately 90.67% of US stocks.
  • Of note is the ratio of ROYALTY PHARMA PLC's sales and general administrative expense to its total operating expenses; merely 5.81% of US stocks have a lower such ratio.
  • The volatility of ROYALTY PHARMA PLC's share price is greater than that of just 1.89% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to RPRX, based on their financial statements, market capitalization, and price volatility, are CHK, CRK, AAT, PXS, and EGLE.
  • To dig deeper into the stock's financial statements, go to RPRX's page on browse-edgar?action=getcompany&CIK=0001802768.

RPRX Valuation Summary

  • In comparison to the median Healthcare stock, RPRX's price/sales ratio is 103.92% higher, now standing at 10.4.
  • Over the past 32 months, RPRX's price/sales ratio has gone down 4.2.

Below are key valuation metrics over time for RPRX.

Stock Date P/S P/B P/E EV/EBIT
RPRX 2023-01-20 10.4 2.2 45.9 42.3
RPRX 2023-01-19 10.3 2.2 45.7 42.2
RPRX 2023-01-18 10.4 2.2 46.1 42.5
RPRX 2023-01-17 10.5 2.3 46.6 42.8
RPRX 2023-01-13 10.6 2.3 47.2 43.2
RPRX 2023-01-12 10.6 2.3 47.0 43.1

RPRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RPRX has a Quality Grade of C, ranking ahead of 62.21% of graded US stocks.
  • RPRX's asset turnover comes in at 0.139 -- ranking 231st of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RPRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.139 1 0.054
2021-03-31 0.138 1 0.056
2020-12-31 0.139 1 0.059

RPRX Price Target

For more insight on analysts targets of RPRX, see our RPRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.43 Average Broker Recommendation 1.67 (Moderate Buy)

RPRX Stock Price Chart Interactive Chart >

Price chart for RPRX

RPRX Price/Volume Stats

Current price $39.19 52-week high $44.75
Prev. close $38.64 52-week low $36.15
Day low $38.50 Volume 1,480,596
Day high $39.20 Avg. volume 1,419,980
50-day MA $40.48 Dividend yield 1.97%
200-day MA $41.57 Market Cap 23.80B

Royalty Pharma PLC (RPRX) Company Bio

Royalty Pharma ist ein US-amerikanisches Finanzunternehmen mit Sitz in New York City. Es besitzt Rechte an verschiedenen Medikamenten, welche von diversen Pharmariesen wie SanofiMerck & Co. oder Novartis vermarktet werden und kassiert dafür Anteile am Vertriebsumsatz (Royalty Interest). (Source:Wikipedia)

RPRX Latest News Stream

Event/Time News Detail
Loading, please wait...

RPRX Latest Social Stream

Loading social stream, please wait...

View Full RPRX Social Stream

Latest RPRX News From Around the Web

Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.

Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

GlobeNewswire | January 18, 2023

Royalty Pharma's (NASDAQ:RPRX) Shareholders Will Receive A Bigger Dividend Than Last Year

The board of Royalty Pharma plc ( NASDAQ:RPRX ) has announced that it will be increasing its dividend by 5.3% on the...

Yahoo | January 12, 2023

Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF Royalties


Royalty Pharma (RPRX) is a profitable, dividend paying company with a business model which involves buying royalty streams. It has provided funding for unprofitable biotech companies, funded R&D projects for large pharma companies and purchased royalties from commercial products such as Humira and Lyrica. The company has a sustainable business model and a solid track record for investing in quality assets. The CF franchise showed significant growth (14% year/year) in addition to accounting for a significant portion of Royalty Pharma’s current revenue ($208 million of $704 million in Q3). The focus of this article is on the deve...

Sage Advisors on Seeking Alpha | January 10, 2023

Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments and the full year 2022 outlook for Net cash provided by operating activities (GAAP financial measure) and Adjusted Cash Receipts ( 1) (non-GAAP financial measure). Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer, will discuss these updates today as part of a webcast presentation at the 41st Annual J.P. Morgan Healthcare Conference to be held at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time.

GlobeNewswire | January 9, 2023

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.

GlobeNewswire | January 9, 2023

Read More 'RPRX' Stories Here

RPRX Price Returns

1-mo -0.84%
3-mo -6.87%
6-mo -7.00%
1-year -0.26%
3-year N/A
5-year N/A
YTD -0.84%
2022 0.99%
2021 -19.09%
2020 N/A
2019 N/A
2018 N/A

RPRX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RPRX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6908 seconds.